ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 2081 • ACR Convergence 2024

    Proteomic Profiling of Urine Reveals Biomarker Candidates for Idiopathic Inflammatory Myopathies

    Xueting Yuan1, Zhengguang Guo2, Jia Shi1, Shuang Zhou3, Chanyuan Wu4, Jiuliang Zhao3, Dong Xu5, Mengtao Li6, Wei Sun2, qian wang6 and Xiaofeng Zeng7, 1Peking Union Medical College, Beijing, China, 2Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China, 3Peking union medical college hospital, Beijing, China, 4Peking Union Medical College Hospital, Chinese Academy of Medical Sciences& Peking Union Medical College, Beijing, China, 5Peking Union Medical College Hospital, Dong Cheng District, Beijing, China, 6Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, 7Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare heterogeneous group of autoimmune diseases characterized by immune-mediated muscle injury. We aimed to examine urine proteomic signatures…
  • Abstract Number: 2323 • ACR Convergence 2024

    The Effect of Biologic Therapies on Serum Metabolic Biomarkers in Patients with Psoriatic Arthritis

    Keith Colaco1, laura bumbulis2, Vinod Chandran1, Richard Cook3, Dafna Gladman4 and Lihi Eder5, 1University of Toronto, Toronto, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3University of Waterloo, Waterloo, Canada, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada

    Background/Purpose: Biologic therapies, such as tumor necrosis factor-alpha inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) may affect the cardio-metabolic profile of patients with psoriatic arthritis (PsA).…
  • Abstract Number: 2535 • ACR Convergence 2024

    The Lipidomic and Proteomic Profiles in Antiphospholipid Syndrome Patients Are Intricately Linked to Disease Pathogenesis and Modulated by Ubiquinol Supplementation

    Chary Lopez-Pedrera1, Beatriz Vellón-García2, Mª Angeles Aguirre-Zamorano3, Sagrario Corrales4, Ismael Sánchez Pareja4, Laura Muñoz-Barrera4, Tomás Cerdó4, Pedro Segui5, Christian Merlo5, María del carmen ábalos-Aguilera5, Nuria Barbarroja4, Alejandro Escudero-Contreras6, Rafaela Ortega-Castro7, José Manuel Villalba8 and Carlos Perez-Sanchez4, 1IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 2Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA3) / Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, 3IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, 4IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 5Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, 6Reina Sofia University Hospital, Córdoba, Spain, 7Hospital Reina Sofía, Cordoba, Andalucia, Spain, 8Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA3), Cordoba, Spain

    Background/Purpose: This study aims to:1) Characterize the circulating lipidomic and proteomic profiles of APS patient and analyse its association with clinical features.2) Investigate the short-term…
  • Abstract Number: 2691 • ACR Convergence 2024

    Transcriptomic Changes in CD4+ T Lymphocytes in Eosinophilic Granulomatosis with Polyangiitis

    Roberto Ríos-Garcés1, Núria Farran1, Salvador Naranjo-Suarez2, Roser Alba-Rovira1, Sergio Prieto-González3, Itziar Tavera-Bahillo1, Roser Solans-Laqué4, Ebymar Arismendi5, Marc Corbera-Bellalta1, Javi Marco-Hernández1, Farah Kamberovic1, Nina Visocnik1, Maria Cid6 and Georgina Espígol-Frigolé1, 1Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, 2Angiogenesis in Liver Disease Research Group, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, 3Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, bar, Spain, 4Internal Medicine Service, Vall d'Hebron Hospital University and Campus, Barcelona, Spain, 5Pneumology Department, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERES, Barcelona, Spain, 6Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain

    Background/Purpose: Eosinophilic Granulomatosis with polyangiitis (EGPA) is a rare systemic autoimmune disorder, included within the ANCA-associated vasculitis. It is characterized by a diverse clinical profile,…
  • Abstract Number: 0098 • ACR Convergence 2024

    Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus

    Marina Barguil Macedo1, Jorge Armando Gonzalez-Chapa1, Anders Bengtsson2, Iva Gunnarsson3, Elisabet Svenungsson4 and Christian Lood1, 1University of Washington, Seattle, WA, 2Lund University, Lund, Sweden, 3Karolinska Institute, Stockholm, Sweden, 4Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Heat shock protein 90 alpha (HSP90α) is an epichaperone present ubiquitously inside the cell, whose dimers function as a foldase that helps the correct…
  • Abstract Number: 0462 • ACR Convergence 2024

    Circulating Mediators of Endothelial Dysfunction as Predictors of Incident Heart Failure in Rheumatoid Arthritis

    Tate Johnson1, Michael Duryee1, Carlos Hunter1, Punyasha Roul2, Joshua Baker3, grant Cannon4, Beth Wallace5, Paul Monach6, Andreas Reimold7, Gail Kerr8, Isaac Smith9, John Richards10, Katherine Wysham11, Gary Kunkel12, Iris Lee13, Daniel Anderson14, Geoffrey Thiele1, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC, Omaha, NE, 3University of Pennsylvania, Philadelphia, PA, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 6VA Boston Healthcare System, Boston, MA, 7Dallas VA Medical Center, Dallas, TX, 8Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 9Duke University Hospital, Durham, NC, 10Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 11VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 12University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 13Washington University in St Louis, Saint Louis, MO, 14University of Nebraska Medical Center, Durham, NC

    Background/Purpose: Endothelial dysfunction, leading to myocardial inflammation and dysfunction, may drive a heightened risk of heart failure (HF) in people with rheumatoid arthritis (RA). Circulating…
  • Abstract Number: 0574 • ACR Convergence 2024

    14-3-3 Eta (η) Auto-Antibody as a Diagnostic Marker in Axial Spondyloarthritis: A Longitudinal Study

    Anthony Marotta1, Walter Maksymowych2, Stephanie Wichuk2 and Navneet Sidhu1, 1Augurex Life Sciences Corp, Vancouver, BC, Canada, 2University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Diagnosis of axial spondyloarthritis (AxSpA) is challenging and often delayed primarily due to the lack of sensitive and specific markers needed for accurate and…
  • Abstract Number: 0695 • ACR Convergence 2024

    Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort

    Stefano Di Donato1, Marco Minerba2, Enrico De Lorenzis3, Collette Hartley4, Lesley-Anne Bissell5, Rebecca Ross6 and Francesco Del Galdo4, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 2Campus Bio-Medico University of Rome, Taranto, United Kingdom, 3Catholic University of the Sacred Heart, Roma, Rome, Italy, 4University of Leeds, Leeds, United Kingdom, 5Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6Medicine and Health, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Systemic Sclerosis (SSc) encompasses limited cutaneous (lc)SSc and diffuse cutaneous (dc)SSc, with lcSSc affecting more than 60% of patients and dcSSc associated being burdened…
  • Abstract Number: 0838 • ACR Convergence 2024

    The Mechanistic Impact of IgA anti-beta-2 Glycoprotein I on Accelerated Atherosclerosis in Primary APS

    Kavya Sugur1, Emily Chong1, Srilakshmi Yalavarthi2, Katarina Kmetova3, Lyndsay Kluge1, Wenying Liang2, Cyrus Sarosh4, NaveenKumar Somanathapura K2, Jacqueline Madison2, Ajay Tambralli2, Jason Knight2 and Yu Zuo2, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI, 3Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, 4University of Michigan, Temperance, MI

    Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease characterized by persistent antiphospholipid antibodies (aPL). APS patients experience significant morbidity and mortality, much of which…
  • Abstract Number: 0964 • ACR Convergence 2024

    Engaging the PD-1 Pathway Attenuates Inflammation Associated Fibrosis in Systemic Sclerosis Fibroblasts and a Preclinical Mouse Model

    Maithri Aspari1, Voon Ong2, Klaus Soendergaard3, Esben Naeser4, Malene Hvid4, Angela Tam5, Shiwen Xu5, Christopher Denton6, David Abraham7, Bent Deleuran1 and Stinne Greisen8, 1Aarhus University, Aarhus, Denmark, 2University College London, London, England, United Kingdom, 3Aarhus University Hospital, Aarhus, Denmark, 4AARHUS UNIVERSITET, AARHUS C, Denmark, 5University College London, London, United Kingdom, 6University College London, Northwood, United Kingdom, 7UCL, London, United Kingdom, 8Aarhus University/Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: The precise molecular mechanisms driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) remain to be elucidated. The immune regulatory programmed cell death protein 1…
  • Abstract Number: 1281 • ACR Convergence 2024

    The Brazilian Registry of Juvenile Dermatomyositis: Relationship Between Ultraviolet Radiation and Laboratory Markers of Juvenile Dermatomyositis in a Tropical Country

    Beatriz Carneiro1, Adriana Elias2, Claudia Saad-Magalhaes3, Erick Kill2, Sylvia Farhat2, Teresa Robazzi4, Ana Julia Moraes5, Sheila Oliveira6, Luciana Carvalho7, Taciana Fernandes3, Carlos Rabello8, Maria Teresa Terreri9, Silvana Sacchetti10, Simone Appenzeller11, Clovis Silva12, Claudio Len13, Darcisio Antonio14, Iloite Scheibel15, Melissa Fraga16, Marcia Bandeira17, Andre Cavalcante18, Ana Paula Vecchi19, Roberto Marini20, Flavio Sztajnbok21, Nadia Aikawa22, lucia Maria Campos2, Katia Kozu2 and Maria Paula Ribeiro2, 1University of São Paulo, São Paulo, SP, Brazil, 2University of Sao Paulo, São Paulo, SP, 3São Paulo State University, Botucatu, 4University of Bahia, Salvador, 5Para Federal University, Belém do Pará, 6Rio de Janeiro Federal University, Rio de Janeiro, Brazil, 7University of São Paulo (Ribeirao Preto), Ribeirao Preto, 8Albert Sabin Children's Hospital, Fortaleza, 9UNIFESP, São Paulo, SP, Brazil, 10Santa Casa Medical School, São Paulo, SP, Brazil, 11Unicamp, Campinas, SP, Brazil, 12Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, 13Federal University of Sao Paulo, São Paulo, SP, 14São Paulo State University, Botucatu, SP, Brazil, 15Conceição's Hospital of Porto Alegre, Porto Alegre, 16Universidade Federal de São Paulo, São Paulo, SP, Brazil, 17Pequeno Principe Hospital, Curitiba, 18Pernambuco Federal University, Recife, 19Children's Hospital of Goiania, Goiânia, 20Campinas State University, Campinas, 21UFRJ/UERJ, SAO PAULO, Brazil, 22Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil

    Background/Purpose: Ultraviolet (UV) waves are risk factors for juvenile dermatomyositis (JDM), when compared to other types of myositis without skin involvement. Patients with JDM have…
  • Abstract Number: 1553 • ACR Convergence 2024

    Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)

    Torsten Witte1, Ruth Fernandez Ruiz2, Nadezda Abramova3, Dominika Weinelt3, Flavie Moreau4, Lena Klopp-Schulze5, Jamie Shaw6, Deborah Denis7 and Joerg Wenzel8, 1Dept of Immunology and Rheumatology, Hannover, Germany, 2Global Clinical Development, EMD Serono, Billerica, MA, 3Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany, 4Global Biostatistics, EMD Serono, Billerica, MA, 5Quantitative Pharmacology, the healthcare business of Merck KGaA, Darmstadt, Germany, 6Companion Diagnostics and Biomarker Strategy, EMD Serono, Billerica, MA, 7EMD Serono, Rockland, MA, 8Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany

    Background/Purpose: Enpatoran, a highly selective, potent and reversible dual toll-like receptor 7/8 (TLR7/8) inhibitor, targets key innate and adaptive immune processes involved in the pathogenesis…
  • Abstract Number: 1792 • ACR Convergence 2024

    CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus

    Lauren Robinson1, Preetha Balasubramanian2, Zurong Wan2, Juan Rodriguez Alcazar2, Marina Lima Silva Santos2, Lynnette Walters3, Jeanine Baisch2, Karen Onel4, Tracey Wright5, Virginia Pascual6 and Simone Caielli2, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Scottish Rite Hospital for Children, Allen, TX, 4HSS, New York, NY, 5UT Southwestern, Plano, TX, 6Weill Cornell Medical College, New York, NY

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type I interferon (IFN) signature.…
  • Abstract Number: 2094 • ACR Convergence 2024

    Cross-sectional Associations of Radiographic Multiple Joint Osteoarthritis and Pain with Demographic and Clinical Characteristics: Design of a Multi-modal Study in Human and Pet Dogs

    Liubov Arbeeva1, Kelly Johnson2, Serena Savage-Guin3, Tessa Walker2, Masataka Enomoto4, Christina Stevens4, Milja Koskinen4, Tracey Cole4, Savannah Aker4, Connor Thonen-Fleck4, Richard Loeser5, Jordan Renner2, Duncan Lascelles6, Yvonne Golightly7 and Amanda Nelson8, 1University of North Carolina, Chapel Hill, Carrboro, NC, 2Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 3Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill,, Chapel Hill, NC, 4Translational Research in Pain and Comparative Pain Research and Education Center, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, 5University of North Carolina, Chapel Hill, NC, 6North Carolina State University, Raleigh, NC, 7University of Nebraska Medical Center, Omaha, NE, 8University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Multiple joint osteoarthritis (MJOA) is a progressive, highly prevalent disease affecting millions of Americans and as well as pet dogs. This preliminary analysis sought…
  • Abstract Number: 2338 • ACR Convergence 2024

    TNF Inhibitor Therapy Increases Absolute Lymphocyte Count Which Is Associated with Lower Mortality in Patients with Psoriatic Arthritis

    Lenche Kostadinova1, Brigid Wilson2, Hinnah Siddiqui2, Sara Behrens3, Angela Gupta4, Megan O'Mara3, Vicky Nahra5, Mahesha Makandura6, Shahdi Malakooti7, Maya Mattar8, David A Zidar1 and Donald D Anthony9, 1Louis Stokes VA Medical Center, cleveland, 2VA Northeast Ohio Healthcare System, Cleveland, 3CWRU, Cleveland, 4Brigham and Women's Faulkner Hospital, Rheumatology Center, Jamaica Plain, 5University Hospitals Cleveland Medical Center, Cleveland, 6Henri Ford Medical Center, Detroit, 7MetroHealth at Case Western Reserve University, Cleveland, 8Louis Stokes VA medical Center, Mayfield Heights, OH, 9Louis Stokes VA Medical Center/Metro Health, Cleveland

    Background/Purpose: Pathogenic inflammation in psoriatic arthritis (PsA) includes TNF pathway engagement, and this is associated with morbidity. Recently, we observed lower absolute lymphocyte count (ALC)…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology